Welcome to our dedicated page for FOXO TECHNOLOGIES SEC filings (Ticker: FOXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FOXO Technologies sits at the crossroads of epigenetics and life insurance, so its SEC filings blend biotech R&D language with actuarial detail. For analysts trying to track patent milestones alongside reinsurance agreements, parsing a 300-page 10-K can feel overwhelming. Questions like “where do I see FOXO insider trading Form 4 transactions?” or “how is DNA-methylation research funded this quarter?” quickly surface. That complexity is why many investors start their research here.
Stock Titan’s AI reads every FOXO quarterly earnings report 10-Q filing the moment it hits EDGAR and distills the revenue shifts, cash-burn trends, and regulatory notes into plain English. Need a quick brief? Our platform flags FOXO 8-K material events explained in under 90 seconds, delivers FOXO Form 4 insider transactions real-time, and links each data point to the original PDF. You’ll also find an AI walkthrough that makes the FOXO annual report 10-K simplified, complete with section-by-section jump links. No more skimming footnotes to understand deferred R&D tax credits or goodwill tests—our expert analysis highlights them for you.
Because FOXO is pioneering longevity underwriting, its proxy statement executive compensation tables reveal how management is incentivized to hit biomarker validation goals, while the FOXO earnings report filing analysis shows progress on lab commercialization. You can monitor FOXO executive stock transactions Form 4 before capital raises, compare cohort survival models across filings, and export the numbers for your own models. Whether you’re focused on understanding FOXO SEC documents with AI or just need a single ratio for tomorrow’s pitch, every disclosure is indexed, searchable, and continuously updated. Explore the complete FOXO library—10-K, 10-Q, 8-K, S-1, and more—FOXO SEC filings explained simply.
FOXO Technologies Inc. disclosed that NYSE Regulation has determined to commence proceedings to delist its Class A common stock from NYSE American under Section 1003(f)(v) of the NYSE American Company Guide, citing the low selling price of the Class A shares. The company attached a press release as Exhibit 99.1 and furnished the information under Item 7.01.
The filing states the disclosure is being furnished, not filed, and includes a standard cautionary statement about forward-looking statements. The report also indicates the registrant is identified as an emerging growth company.
FOXO Technologies Inc. (NYSE American: FOXO) filed an 8-K (Item 7.01) on 6-Aug-2025 disclosing two M&A updates. The company has signed a non-binding agreement to acquire an assisted-living and memory-care facility in South Florida. In addition, management states it is in the advanced stages of negotiating a definitive agreement to purchase Vector Biosource, Inc., a transaction previously announced.
The filing furnishes, rather than files, a press release (Ex. 99.1); therefore the information is not subject to Section 18 liabilities and is excluded from incorporation by reference unless specifically included elsewhere. No purchase price, financing details, or closing timelines were provided. All statements are forward-looking and contingent on concluding definitive agreements; closing remains uncertain.
FOXO Technologies filed an 8-K announcing a Charter Amendment that executed a 1-for-1.99 reverse stock split of its Class A common stock. The split became effective at 4:01 p.m. ET on 27 Jul 2025; shares began trading on a post-split basis on 28 Jul 2025 under new CUSIP 351471 503 while retaining ticker FOXO on NYSE American. Every 1.99 pre-split shares were combined into one share, keeping the $0.0001 par value unchanged. Fractional positions were rounded up to the next whole share, eliminating fractional holdings.
The reverse split roughly halves the public float, a measure typically used to elevate the market price and maintain exchange listing compliance. No other financial results, transactions, or operational changes were disclosed. Exhibit 3.1 contains the full Certificate of Amendment, and Exhibit 104 supplies the Inline XBRL cover data.
FOXO Technologies (NYSE:FOXO) amended its Certificate of Incorporation on June 25 2025 to authorize up to 4,000,000 shares of Series E Cumulative Redeemable Secured Preferred Stock. The new series carries a $25.00 liquidation preference, semi-annual cumulative cash dividends plus stock dividends, is non-voting and non-convertible, and is secured by the stock of wholly-owned FOXO Acquisition Corp. The authorization gives the board flexibility to raise roughly $100 million in preferred equity while ranking senior to common stock. A press release (Ex. 99.1) announcing the designation was furnished under Item 7.01; no financial statements were included.
FOXO Technologies (NYSE American: FOXO) filed an 8-K reporting that a stockholder holding 82.08% of voting power delivered written consent approving nine share-related actions.
- Items 1-7: Authorize issuance of >20% of outstanding shares upon conversion of Series A-D preferred stock, convertible notes, an exchange agreement, finder fees and inducement shares, satisfying NYSE American Section 713.
- Item 8: Issue 40,000 shares to director Bret Barnes under his agreement, per Section 711.
- Item 9: Permit a reverse stock split at a 1-for-1.99 ratio any time before 6 Nov 2025 at the board’s discretion.
A preliminary Schedule 14C has been filed; actions become effective 20 days after mailing the definitive statement.
FAQ
What is the current stock price of FOXO TECHNOLOGIES (FOXO)?
What is the market cap of FOXO TECHNOLOGIES (FOXO)?
